Ipsen announced that the FDA has approved a supplemental indication for Somatuline Depot (lanreotide) Injection 120 mg for the treatment...
Ipsen has announced that Somatuline Depot (lanreotide) Injection 120 mg was approved by the FDA for the treatment of adult...
Ipsen Biopharmaceuticals announced that Endocrine Practice has published Phase III clinical trial results examining the efficacy and safety of Somatuline...
Ipsen has submitted national marketing authorization variations for Somatuline Autogel 120mg injection to the drug regulatory authorities in 25 countries...